| 4.75 -0.02 (-0.42%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.83  |
1-year : | 14.42 |
| Resists | First : | 9.27 |
Second : | 12.35 |
| Pivot price | 6.85 |
|||
| Supports | First : | 4.29 |
Second : | 3.57 |
| MAs | MA(5) : | 6.44 |
MA(20) : | 6.7 |
| MA(100) : | 12.08 |
MA(250) : | 10.95 |
|
| MACD | MACD : | -1 |
Signal : | -1 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 51.1 |
| RSI | RSI(14): 27.9 |
|||
| 52-week | High : | 18.54 | Low : | 4.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CVRX ] has closed below the lower bollinger band by 2.7%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.96 - 5 | 5 - 5.02 |
| Low: | 4.24 - 4.27 | 4.27 - 4.3 |
| Close: | 4.7 - 4.76 | 4.76 - 4.8 |
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sat, 10 May 2025
CVRx, Inc. (NASDAQ:CVRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Fri, 09 May 2025
CVRx Earnings Call: Growth Amidst Challenges - TipRanks
Fri, 09 May 2025
CVRx stock downgraded at J.P. Morgan on Q1 miss (CVRX:NASDAQ) - Seeking Alpha
Fri, 09 May 2025
Demystifying CVRx: Insights From 4 Analyst Reviews - Nasdaq
Fri, 09 May 2025
Investors Appear Satisfied With CVRx, Inc.'s (NASDAQ:CVRX) Prospects As Shares Rocket 25% - simplywall.st
Fri, 09 May 2025
CVRx: Q1 Earnings Snapshot - New Haven Register
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 26 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 71.1 (%) |
| Shares Short | 1,220 (K) |
| Shares Short P.Month | 2,270 (K) |
| EPS | -2.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.8 |
| Profit Margin | -117 % |
| Operating Margin | -67 % |
| Return on Assets (ttm) | -30 % |
| Return on Equity (ttm) | -81.6 % |
| Qtrly Rev. Growth | 35.7 % |
| Gross Profit (p.s.) | 1.64 |
| Sales Per Share | 1.96 |
| EBITDA (p.s.) | -2.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -1.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.69 |
| Price to Sales | 2.41 |
| Price to Cash Flow | -3.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|